Show simple item record

dc.contributor.authorStrengert, Monika
dc.contributor.authorBecker, Matthias
dc.contributor.authorRamos, Gema Morillas
dc.contributor.authorDulovic, Alex
dc.contributor.authorGruber, Jens
dc.contributor.authorJuengling, Jennifer
dc.contributor.authorLürken, Karsten
dc.contributor.authorBeigel, Andrea
dc.contributor.authorWrenger, Eike
dc.contributor.authorLonnemann, Gerhard
dc.contributor.authorCossmann, Anne
dc.contributor.authorStankov, Metodi V
dc.contributor.authorDopfer-Jablonka, Alexandra
dc.contributor.authorKaiser, Philipp D
dc.contributor.authorTraenkle, Bjoern
dc.contributor.authorRothbauer, Ulrich
dc.contributor.authorKrause, Gérard
dc.contributor.authorSchneiderhan-Marra, Nicole
dc.contributor.authorBehrens, Georg M N
dc.date.accessioned2021-09-14T11:04:23Z
dc.date.available2021-09-14T11:04:23Z
dc.date.issued2021-08-12
dc.identifier.citationEBioMedicine. 2021 Aug;70:103524. doi: 10.1016/j.ebiom.2021.103524. Epub 2021 Aug 12.en_US
dc.identifier.pmid34391096
dc.identifier.doi10.1016/j.ebiom.2021.103524
dc.identifier.urihttp://hdl.handle.net/10033/623029
dc.description.abstractBackground: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. Methods: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. Findings: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. Interpretation: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. Funding: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectDialysisen_US
dc.subjectImmunocompromiseden_US
dc.subjectProtective immunityen_US
dc.subjectSARS-CoV-2en_US
dc.subjectVariants of concernen_US
dc.subjectmRNA vaccinationen_US
dc.titleCellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.en_US
dc.typeArticleen_US
dc.identifier.eissn2352-3964
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalEBioMedicineen_US
dc.source.volume70
dc.source.beginpage103524
dc.source.endpage
refterms.dateFOA2021-09-14T11:04:24Z
dc.source.journaltitleEBioMedicine
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Strengert et al.pdf
Size:
784.7Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International